The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infa rct ion and ischaemic stroke , and an increased risk of major and minor bleeding compared with aspirin alone .
According to GRADE criteria , the quality of evidence was moderate for all outcomes except all-cause mortality ( low quality evidence ) and adverse events ( very low quality evidence )
BACKGROUND Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease .
Adding a second antiplatelet drug to aspirin may produce additional benefit for people at high risk and people with established cardiovascular disease .
This is an up date to a previously published review from 2011 .
OBJECTIVES To review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease , ischaemic cerebrovascular disease , peripheral arterial disease , or were at high risk of atherothrombotic disease , but did not have a coronary stent .
Twelve-Month Results of a Randomized Trial Comparing Mono With Dual Antiplatelet Therapy in Endovascularly Treated Patients With Peripheral Artery Disease
Purpose To present the 12-month results of a trial investigating the effects of dual antiplatelet therapy on  target lesion revascularization ( TLR ) after balloon angioplasty ± stenting in the femoropopliteal segment . Methods A prospect i ve , r and omized , single-center , double-blinded and placebo-controlled clinical trial r and omly assigned 40 patients to receive pre- and postinterventional therapy with aspirin and clopidogrel . Another 40 patients received the same doses of aspirin and placebo instead of clopidogrel . Clopidogrel and placebo were stopped after 6 months , and patients remained on aspirin only . At 12 months after the intervention , 36 clopidogrel patients and 37 placebo patients were reevaluated . Results At 6 months , clopidogrel patients had significantly lower rates of TLR compared to placebo patients [ 2 ( 5 % ) vs. 8 ( 20 % ) , p=0.04 ] . After stopping clopidogrel/placebo after 6 months , there was no significant difference in TLR at 12 months after treatment [ 9 ( 25 % ) clopidogrel vs. 12 ( 32.4 % ) placebo , p=0.35 ] . Mortality was 0 vs. 1 in the placebo group at 6 months ( p=0.32 ) and 0 vs. 3 at 12 months ( p=0.08 ) . Conclusion In contrast to the first report of a reduction in the TLR at 6 months , this advantage of dual antiplatelet therapy does not persist after stopping clopidogrel . Prolonged dual therapy ( > 6 months ) should be considered in patients who are at high risk for restenosis
The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infa rct ion and ischaemic stroke , and an increased risk of major and minor bleeding compared with aspirin alone .
According to GRADE criteria , the quality of evidence was moderate for all outcomes except all-cause mortality ( low quality evidence ) and adverse events ( very low quality evidence )
BACKGROUND Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease .
Adding a second antiplatelet drug to aspirin may produce additional benefit for people at high risk and people with established cardiovascular disease .
This is an up date to a previously published review from 2011 .
OBJECTIVES To review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease , ischaemic cerebrovascular disease , peripheral arterial disease , or were at high risk of atherothrombotic disease , but did not have a coronary stent .